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Arylimidamides (AIAs) have been shown to have considerable biological activity against intracellular pathogens, including
Trypanosoma cruzi, which causes Chagas disease. In the present study, the activities of 12 novel bis-AIAs and 2 mono-AIAs
against different strains of T. cruzi in vitro and in vivo were analyzed. The most active wasm-terphenyl bis-AIA (35DAP073),
which had a 50% effective concentration (EC50) of 0.5M for trypomastigotes (Y strain), which made it 26-fold more effective
than benznidazole (Bz; 13M). It was also active against the Colombiana strain (EC50 3.8M). Analysis of the activity against
intracellular forms of the Tulahuen strain showed that this bis-AIA (EC50 0.04M) was about 100-fold more active than Bz (2
M). The trypanocidal effect was dissociated from the ability to trigger intracellular lipid bodies within host cells, detected by oil
red labeling. Both an active compound (35DAP073) and an inactive compound (26SMB060) displayed similar activation profiles.
Due to their high selectivity indexes, two AIAs (35DAP073 and 35DAP081) were moved to in vivo studies, but because of the re-
sults of acute toxicity assays, 35DAP081 was excluded from the subsequent tests. The findings obtained with 35DAP073 treat-
ment of infections caused by the Y strain revealed that 2 days of therapy induced a dose-dependent action, leading to 96 to 46%
reductions in the level of parasitemia. However, the administration of 10 daily doses in animals infected with the Colombiana
strain resulted in toxicity, preventing longer periods of treatment. The activity of the combination of 0.5 mg/kg of body weight/
day 35DAP073 with 100 mg/kg/day Bz for 10 consecutive days was then assayed. Treatment with the combination resulted in the
suppression of parasitemia, the elimination of neurological toxic effects, and survival of 100% of the animals. Quantitative PCR
showed a considerable reduction in the parasite load (60%) compared to that achieved with Bz or the amidine alone. Our results
support further investigations of this class with the aim of developing novel alternatives for the treatment of Chagas disease.
Chagas disease (CD) is caused by the obligate intracellular pro-tozoan Trypanosoma cruzi. More than a hundred years after
its discovery (1), CD is still an important public health problem,
and about 6 million to 7 million people, mostly in Latin America,
are estimated to be infected worldwide (2). Of these infected in-
dividuals, 30 to 40% develop cardiomyopathy and/or digestive
syndromes (3). For over 4 decades, nifurtimox [3-methyl-4-(5=-
nitrofurfurylideneamine tetrahydro-4H-1,4-tiazine-1,1-dioxide)]
and benznidazole (Bz; N-benzyl-2-nitroimidazole acetamide),
which have been used as empirical therapy for CD, have remained
the sole treatment options (4). Both have several limitations, in-
cluding a variety of adverse effects and limited efficacy in the later
chronic phase of infection (5, 6), characteristics which strengthen
the need for new trypanocidal compounds that overcome these
limitations.
Classic aromatic diamidines (ADs) are DNA minor groove
binders with recognized broad-spectrum antimicrobial and anti-
tumor activities (7). ADs, such as pentamidine, diminazene, and
propamidine, have been used as therapies in human and veteri-
narymedicine for decades, but despite their excellent antiparasitic
effects, they have relevant drawbacks that include low bioavail-
ability and side effects. To overcome these limitations, new ana-
logues have been synthesized and tested in vivo and in vitro (7).
Several ADs and related compounds have been screened for their
activities against T. cruzi and have shown promising results, at
least in part due to their capacity to alter the kinetoplast DNA
molecule (8, 9). Arylimidamides (AIAs; formerly called “reversed”
amidines, because of the reversed position of the nitrogen and
carbon atoms compared to their orientation in classic aromatic
amidines) are the most effective amidine analogues tested against
T. cruzi in vitro and in vivo (9–12).
Lipid bodies (LBs) consist of a nucleus of cholesteryl esters and
triglycerides surrounded by a single monolayer of phospholipids.
LBs are considered not only lipid storage compartments but also
intracellular sites formany biological events, like cellular signaling
and activation, regulation of lipid metabolism, membrane traf-
ficking, and regulation of inflammatory mediators (13, 14). Re-
cent studies proposed a dynamic role of LBs in the control of
pathogen infections due to their localization inside the parasito-
phorous vacuoles in intracellular parasites like T. cruzi (15).
Our present study focused on an analysis of the activities of 12
novel bis-AIAs and 2 mono-AIAs against bloodstream trypomas-
tigotes (BTs) and intracellular forms of T. cruzi (the Tulahuen, Y,
and Colombiana strains) in vitro. The most potent and most se-
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lective compound tested, 35DAP073, underwent further screen-
ing in experimental mouse models of acute parasite infection
(with strains Y and Colombiana) alone or combined with the ref-
erence drug (Bz) with the aim of contributing to the search for
novel alternative protocols for the treatment of CD.
MATERIALS AND METHODS
Synthesis of the arylimidamides. The synthesis of the four m-terphenyl
bisarylimidamides 35DAP069, 35DAP073, 35DAP077, and 35DAP081
and the two monoarylimidamides 35DAP092 and 38DAP096 (Fig. 1) has
been described previously (16), wherein the final step was the reaction of
the appropriate terphenyl amine or diamine with benzonitrile or 2-cyan-
opyridine using sodium bis(trimethylsilyl)amide in tetrahydrofuran.
Similar reactions involving 1,4-diphenylenediamine and 2,5- or 2,6-di-
aminopyridine were employed for the synthesis of 19SAB003, 19SAB005,
19SAB007, and 28SMB008 (17) (Fig. 2). Compounds 23SMB046,
23SMB050, 26SMB060, and 27SMB005 (Fig. 3) were prepared by a pre-
viously described methodology from the methyl imidate derivatives of 2-
or 4-cyanopyridine and the appropriate ,-diaminoalkane (18). All 14
compounds were isolated as their hydrochloride salts. Experimental de-
tails and physical data for the compounds shown in Fig. 2 and 3 are given
in Text S1 in the supplemental material.
Stock solutions of the tested compounds. The studied molecules
were prepared in dimethyl sulfoxide (DMSO; Sigma-Aldrich), with the
final concentration of the solvent (obtained by dilution using RPMI 1640
medium) never exceeding 0.6% and 10% for the in vitro and in vivo anal-
yses, respectively. The solvent did not exert toxicity on parasites or mam-
malian host cells (data not shown). Bz was purchased from the Labo-
ratório Farmacêutico do Estado de Pernambuco (LAFEPE), Brazil. Bz was
dissolved in distilled and sterile water supplemented with 3% Tween 80
and does not have any detectable effect on mice (19).
Mammalian cell cultures.Primary cultures of embryonic cardiac cells
(CCs) were obtained from Swiss Webster mice as previously reported
(20). After purification, the CCs were seeded into 24- and 96-well micro-
plates containing gelatin-coated coverslips at densities of 0.2  106 and
0.05 106 cells/well, respectively, as reported previously (18). The cardiac
cell cultures were then sustained at 37°C in Dulbecco’s modified Eagle
medium (DMEM; without phenol red; Sigma-Aldrich) supplemented
with 10% horse serum, 5% fetal bovine serum, 2.5 mM CaCl2, 1 mM
L-glutamine, and 2% chicken embryo extract. Additionally, mouse L929
fibroblasts were cultivated (4  103 cells/well in 96-well microplates) at
37°C in RPMI 1640 medium (pH 7.2 to 7.4) without phenol red (Gibco
BRL) supplemented with 10% fetal bovine serum and 2 mM glutamine
(RPMI), as reported previously (21).
In vitro cytotoxicity tests. CCs and L929 cell cultures were incubated
at 37°C for different periods of time (24 to 96 h) with increasing concen-
trations of each compound (up to 96 M) diluted in DMEM (without
phenol red). Next, mammalian cell morphology and spontaneous con-
tractibility (of CCs) were evaluated by light microscopy, and cell viabil-
ity was determined by a colorimetric assay using 10 l alamarBlue
(Invitrogen), which was added to each well. After incubation for 24 h,
the absorbance at 570 and 600 nm was determined and the results were
determined following the manufacturer’s instructions. Then, the con-
centration that reduced cell viability by 50% (LC50) was calculated as
reported previously (21).
Parasites. Bloodstream trypomastigote (BT) forms of the Y and Co-
lombiana strains ofT. cruziwere obtained from the blood of infectedmale
SwissWebster mice at the peak of parasitemia (12). Immediately after the
purification step, the parasites were resuspended in RPMI 1640 medium
(pH 7.2 to 7.4) without phenol red (Gibco BRL) supplemented with 10%
fetal bovine serum (FBS) and 2 mM glutamine, as reported previously
FIG 1 Structures of mono- and bisarylimidamide derivatives of m-terphenyl.
FIG 2 Synthesis of bisarylimidamide derivatives of benzene and pyridine.
Reagents and conditions were as follows: a, sodium bis(trimethylsilyl)amide;
tetrahydrofuran; and 25°C.
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(18). The effect against the intracellular forms was investigated through
the use of L929 cell lineages infectedwith tissue culture-derived trypomas-
tigotes (the Tulahuen strain expressing theEscherichia coli-galactosidase
gene), using a 10:1 parasite/host cell ratio. The incubation with the tested
compounds was performed for 96 h, and previously established protocols
were followed (21). Alternatively, CCs were infected (ratio, 10:1) with
bloodstream trypomastigotes (Y strain). After 24 h of interaction, the
infected cultures were rinsed and then exposed for 48 h to nontoxic con-
centrations of the amidines, which had previously been screened onmam-
malian host cells.
Trypanocidal analysis.TheBT forms of theY andColombiana strains
(5  106 per ml) were incubated for up to 24 h at 37°C in RPMI in the
presence of serial dilutions of the compounds (0 to 32M), and parasites
incubated with culture medium alone were used as controls. After incu-
bation with the compound, the parasite death rates were determined by
light microscopy through the direct quantification of the number of live
parasites using a Neubauer chamber, and the compound concentration
that reduced the number of parasites by 50% (the 50% effective concen-
tration [EC50]) was calculated. Also, the compound concentration that
reduced the number of parasites by 90% (EC90) was further calculated in
intracellular assays using the Y strain (18). For the assay with intracellular
forms, cardiac cell cultures and cells of the L929 cell linewere used as hosts
for infection with the Y and Tulahuen strains, respectively. Briefly, Tula-
huen-infected L929 cell cultures were exposed to 10 M (corresponding
to the EC90 value of Bz, as reported elsewhere [18]) each compound di-
luted in RPMI, and the compounds that resulted in a50% reduction of
the parasite infection index were further screened at increased concentra-
tions to determine the EC50s (18). After 96 h of incubation with the com-
pound at 37°C, chlorophenol red glycoside (500 M; Sigma-Aldrich) in
0.5% Nonidet P-40 was added to each well, and the plate was incubated
for 18 h at 37°C. Next, the absorbance at 570 nm was measured. Unin-
fected and T. cruzi-infected cultures exposed to the vehicle and Bz were
run in parallel. The results are expressed as the percentage of T. cruzi
growth inhibition in compound-tested host cells compared to that in the
infected but untreated cells (21). Triplicate samples were run in the same
plate, and at least two assays were performed in each analysis. For the
analysis of the effects of the test compounds against intracellular amasti-
gotes of the Y strain, after 24 h of parasite-host cell interaction, the in-
fected CCs were washed to remove free parasites and then incubated for
another 48 h with increasing concentrations of the test compounds. CCs
were maintained at 37°C in an atmosphere of 5% CO2 and air, and the
mediumwas replaced every 24 h. Then, the sampleswere fixed and stained
with Giemsa solution (Sigma-Aldrich), and the number of infected host
cells and the number of parasites per infected host cell were determined by
light microscopy analysis (18). Only characteristic T. cruzi cells with nu-
clei and kinetoplasts were counted as surviving parasites, since irregular
structures could indicate parasites undergoing death. Compound activity
was estimated by calculating the percentage of inhibition upon the infec-
tion index (the percentage of infected host cells multiplied by the average
number of intracellular amastigotes per infected host cell) (12). At least
two assays were performed in duplicate in each analysis.
LB labeling. To determine the biogenesis of lipid bodies (LBs) in car-
diac cell cultures exposed to amidines, untreated CCs were incubated for
2 to 48 hwith the studied compounds at the corresponding EC50s (against
intracellular forms of theY strain determined earlier) and thenfixed for 10
min with 3.7% formaldehyde in Ca2- and Mg2-free Hanks balanced
salt solution (pH 7.4). Next, the samples were rinsed twice using distilled
water, incubated for 5min in absolute propylene glycol, and stained for 10
min in 0.5% oil red (Sigma-Aldrich). The cultures were incubated for 3
min with 85% propylene glycol and, finally, rinsed twice using distilled
water. The samples were incubated or not with 1g/ml 4,6-diamidino-2-
phenylindole (DAPI; Sigma-Aldrich) forDNA staining (host cells nuclei),
rinsed with saline buffer, dried, and mounted using aqueous mounting
medium [2.5% 1.4-diazabicyclo-(2.2.2)octane (DABCO)], and the fluo-
rescencewas analyzedwith a63 oil objective in a Zeiss photomicroscope
(AxioCam) equipped with epifluorescence (Zeiss Inc., Thornwood, NY)
and by using a filter set for UV-excited probes. Images were captured
using the software AnalySIS OPTI. As positive control, 2 M oleic acid
(Sigma-Aldrich)was used to trigger the biogenesis of the lipid bodies (22).
In vivo acute toxicity. In order to determine the no-observed-ad-
verse-effect level (NOAEL), increasing doses of the tested compounds (up
to 200 mg/kg of body weight) were injected by the intraperitoneal (i.p.)
route individually in female SwissWebster mice (weight, 20 to 23 g; n 2
mice per assay for two assays). Treated animals were inspected for toxic
and subtoxic symptoms according to the Organization for Economic Co-
operation and Development (OECD) guidelines. At 48 h after compound
injection, theNOAELvalueswere determined as reported previously (23).
Biochemical analysis.At 48 h after compound administration,mouse
blood was collected and immediately submitted to biochemical analysis
for determination of the levels of plasma markers, including urea (blood
urea nitrogen [BUN]), alanine aminotransferase (ALT), aspartate amino-
transferase (AST), and creatine kinase (CK), which was performed at the
animal facilities (CECAL/Fiocruz platform) of the Oswaldo Cruz Foun-
dation (Rio de Janeiro, Brazil) using an Ortho Clinical Vitros 250 chem-
istry system (Johnson & Johnson), as reported previously (23).
In vivo infection. Male Swiss Webster mice (weight, 18 to 20 g) ob-
tained from the animal facilities of CECAL were housed at a maximum of
6 per cage, kept in a specific-pathogen-free (SPF) room at 20 to 24°C
under a 12- light and 12-h dark cycle, and provided sterilized water and
chow ad libitum. The animals were allowed to acclimate for 7 days before
starting the experiments. Infection was performed by i.p. injection of 104
and 5 103 bloodstream trypomastigotes (the Y andColombiana strains,
respectively). Age-matched noninfected mice were maintained under
identical conditions (12).
Treatment schemes. AIAs were first dissolved in DMSO and then
freshly diluted with sterile distilled water. The stock solution of benznida-
zole (N-benzyl-2-nitroimidazole acetamide) was prepared in sterile dis-
tilledwater with 3%Tween 80 (Sigma-Aldrich). The animals were divided
into the following groups (5 animals per group): uninfected (noninfected
and nontreated), untreated (infected but treated only with vehicle), and
treated (infected and treated with the compounds) groups. The therapy
(once a day) was performed by the use of different schemes (see Text S2 in
FIG 3 Synthesis of bisarylamidamide derivatives of n-alkanes. Reagents and conditions were as follows: a, 4 M HCl in dioxane; methanol; and 25°C.
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the supplemental material). In the first set of assays, T. cruzi (Y strain)-
infected mice were treated for only 2 days (at 5 days postinfection [dpi]
and at 8 dpi, which correspond to the time of parasitemia onset and the
time of peak parasitemia in this experimental model, respectively), using
5 to 20mg/kg/day AIA (administered i.p.) and 100mg/kg/day Bz (admin-
istered orally). In the second set of experiments, mice were infected with
the Colombiana strain and the therapy started at 10 dpi (the time of
parasitemia onset in this animal model) were treated for 10 consecutive
days with 35DAP073 alone (5 mg/kg/day) or in combination with Bz (0.5
mg/kg/day AIA plus 100 mg/kg/day of Bz). In all assays, only mice with
positive parasitemia were used in the infected groups.
Parasitemia and mortality rates. Parasitemia was individually checked
by direct microscopic counting of the number of parasites in 5 l of blood,
and themicewere checked formortality daily until 30 days posttreatment.
Mortality is expressed as the percent cumulative mortality (CM) as de-
scribed before (18).
Determinationofbloodparasite loadbyqPCR.Forquantitative real-
time PCR (qPCR), 500 l blood was diluted in a 1:2 volume of guanidine
solution (6 M guanidine-HCl, 0.2 M EDTA; Sigma-Aldrich) and heated
for 90 s in boiling water. Blood samples in guanidine-EDTA were pro-
cessed using a QIAamp DNA minikit (Qiagen) (24). Quantitative real-
time multiplex PCR assays using TaqMan probes targeting T. cruzi satel-
lite nuclear DNA and the internal amplification control (IAC; plasmid
pZErO-2 containing an insert from the Arabidopsis thaliana aquaporin
gene) were performed as described previously (25). The standard curves
for absolute quantification were constructed with serial dilutions of total
DNA ranging from 105 parasite equivalents to 0.5 parasite equivalents per
ml of blood obtained with a negative blood sample in guanidine-EDTA
spiked with 105 parasite equivalents per milliliter of blood.
Ethics. All procedures were carried out in accordance with the guide-
lines established by the FIOCRUZ Committee of Ethics for the Use of
Animals (CEUA LW16/14).
Statistical analysis. The data represent the means 	 standard devia-
tions (SDs) from 2 experiments run in duplicate, and statistical analysis
was performed by analysis of variance (ANOVA), with significance being
set at a P value of0.05 (23).
RESULTS
The phenotypic analysis of BT forms (Y strain, discrete typing unit
[DTU] II) showed that all studied compounds were active against
the parasite. The response to compounds 35DAP073, 35DAP081,
35DAP077, and 35DAP092 was time dependent, with the com-
pounds exhibiting EC50s ranging from 0.7 to 28 M and 0.5 to 10
M after 2 and 24 h of incubation, respectively, while the EC50 of
Bz was 13Mafter 24 h (Table 1). Among these four compounds,
the most active were 35DAP073 and 35DAP081, and both also
displayed the highest selectivity indexes (SIs; 64 and 53, respec-
tively). Statistical analysis revealed that 35DAP073, 35DAP081,
and 35DAP092 presented efficacy superior to that of Bz (P 

0.05). When BT forms of the Colombiana strain (DTU I) were
assayed, both amidines showed a trypanocidal effect, with the
EC50s of 35DAP073 and 35DAP081 being 3.8	 2.8 and 1.9	 0.4
M, respectively. 35DAP073 and 35DAP081 were very active
against intracellular forms of both the Tulahuen (Table 2) and Y
(Table 3) strains of T. cruzi, which are representatives of DTUs VI
and II, respectively, andweremore potent than Bz (P 0.05). The
m-terphenyl bis-AIA 35DAP073 showed higher activity, indicated
by the lower EC90 values (87 nM) after 48 h of incubation, andwas
about 126-fold more effective than Bz, and it also exhibited the
highest SI (SI, 2,000) (Table 3).
As 35DAP073 was more effective against intracellular forms
than BT forms (Y strain; Tables 1 and 3) and the biogenesis of LBs
may be induced by different stimuli (26), the induction of LB
biogenesis during incubation of uninfected CCs with this amidine
was comparedwith that during incubation of uninfectedCCswith
another molecule not active against T. cruzi in vitro (26SMB060).
After incubation for different lengths of time (2 to 48 h), our data
revealed that both amidines were able to induce LB biogenesis at
similar levels very quickly, since strong LB formation compared to
that in the untreated group was seen as soon as only 2 h posttreat-
ment, and the profile was similar to that obtainedwith the positive
control (oleic acid) (Fig. 4). A large number of LBs was also ob-
served after 24 h of amidine exposure, and the levels were main-
tained up to 48 h, although oleic acid caused the progressive and
continuous formation of LB (increases in the number and vol-
ume) (Fig. 4).
Next, due to the high activity and selectivity of 35DAP073 and
35DAP081, Swiss Webster mice were used to determine the
NOAEL values of the two compounds. 35DAP073 proved to be
TABLE 1 In vitro activities (EC50s) and SIs of the tested compounds
against BT forms of Trypanosoma cruzi Y
Compound
EC50 (M)
SI at 24 h2 h 24 h
35DAP096 32 32 1
35DAP073 0.7	 0.14 0.5	 0.2a 64
35DAP077 28	 0.3 10	 5.5 2
35DAP081 2	 0.8 0.6	 0.2a 53
38DAP092 16	 11 7	 1.2a 5
38DAP096 32 24	 1 1.3
19SAB003 32 32 1
19SAB005 32 32 1
19SAB007 32 32 1
28SMB008 32 32 1
23SMB046 32 32 1
23SMB050 32 32 1
26SMB060 32 32 1
27SMB005 32 32 1
Benznidazole 100 13	 2 77b
a P
 0.05 by ANOVA.
b The datum is from Timm et al. (18).
TABLE 2 In vitro activities (EC50s) and SIs of the tested compounds
against intracellular forms of Trypanosoma cruzia
Compound EC50 (M) SI
35DAP073 0.04	 0.005b 480
35DAP081 0.79	 0.06b 18
Benznidazole 2	 0.8 51
a The Trypanosoma cruzi Tulahuen strain expressing the Escherichia coli -galactosidase
gene was used to infect L929 cells, which were treated for 96 h at 37°C.
b P
 0.05 by ANOVA.
TABLE 3 In vitro activities (EC50s) and SIs of the tested compounds
against intracellular forms of Trypanosoma cruzi Y in CCs at 48 h after
incubation at 37°C
Compound EC50 (M) EC90 (M) SI
a
35DAP073 0.016	 0.007b 0.087	 0.009b 2,000
35DAP081 0.23	 0.06b 0.9	 0.05b 139
Benznidazole 3.6	 1.7 11	 2.7 277
a The SI data are related to the EC50 values.
b P
 0.05 by ANOVA.
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less toxic at all doses tested, presenting an NOAEL of 25 mg/kg,
while 35DAP081 showed an NOAEL of
12.5 mg/kg (Table 4).
Plasma biochemical analysis (P 0.1) after 48 h of compound
administration did not show any statistically significant differ-
ences in the levels of ALT, AST, CK, and BUN among all tested
groups (Table 5). Due to the findings of these preliminary acute
toxicity studies, only 35DAP073 was evaluated in in vivo mod-
els of acute T. cruzi infection using nontoxic doses (up to 25
mg/kg/day). In parallel, a control group was orally treated with Bz
(100 mg/kg/day) (Fig. 5).
Our data demonstrated a dose-dependent effect of treatment
with 35DAP073 at concentrations of up to 20 mg/kg/day, which
led to 96 to 46% reductions in the levels of parasitemia (Fig. 5).
The animal survival rates achieved 100% when the mice were
treated with 5 and 10 mg/kg/day of 35DAP073, which was similar
to the results obtained with 100 mg/kg/day Bz (Fig. 5). However,
FIG 4 Differential interference contrast (DIC) microscopy analysis of oil red labeling of cardiac cells untreated (A to C) and exposed to oleic acid (D to
F), 35DAP073 (G to I), and 26SMB060 (J to L) for 2 h (A, D, G, J), 24 h (B, E, H, K), and 48 h (C, F, I, L) at 37°C. (M to T) Detailed oil red labeling of cardiac
cells by differential interference contrast (M, O, Q, and S) and fluorescence microscopy using DAPI staining of mammalian cell nuclei (N, P, R, and T)
after 24 h of incubation with 35DAP073 (Q and R) and 35DAP060 (S and T), showing the accumulation of lipid bodies randomly distributed throughout
the cytoplasm.
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as the tested compound did not result in the complete suppression
of the blood parasite load, a longer period of therapy (10 days
using 5 mg/kg/day) was next investigated with mice infected with
5  103 bloodstream trypomastigote forms of the Colombiana
strain. Also, 35DAP073 combined with Bz (treatment for 10 days
using 0.5 mg/kg/day 35DAP073 and 100 mg/kg/day Bz) was as-
sayed in parallel using the same experimental model described
above, with the therapy being started at the time of parasitemia
onset. Our findings showed that 5 mg/kg/day of 35DAP073 com-
pletely suppressed the parasitemia and gave 100%animal survival,
as did Bz (Fig. 6). However, at the end of the therapy period (the last
dayof 35DAP073 administration), themicepresented someundesir-
able neurological toxic disorders (tremors, shaking, ataxia) that were
no longer observed after 48 h posttreatment (data not shown). The
combination of 0.5 mg/kg/day of this amidine with Bz resulted in
parasitemia suppression, 100% animal survival, and no toxic
events (Fig. 6). Analysis by qPCR showed that although no statis-
tically significant difference in blood parasite loads was found
among the tested groups (P  0.05), monotherapy with Bz and
35DAP073 resulted in mean values of 204 and 265 parasite equiv-
alents (Par. Eq.)/ml, respectively, while the association of Bz with
the AIA induced a higher reduction (60%) of the blood parasite
load (82 Par. Eq./ml) (Fig. 7).
DISCUSSION
The current therapies for Chagas disease remain unsatisfactory
due to their various side effects and limited efficacies (27). Ami-
dines have been used as antiparasitic agents for decades in human
and veterinary medicine but show important limitations, such
as the need for parenteral administration and undesirable side
effects (7). In order to overcome these limitations, novel ami-
dines have been synthesized and phenotypic analysis of novel
amidines has been conducted in vivo and in vitro (12, 28).
Among these, arylimidamides (AIAs) showed considerable bi-
ological activity against several intracellular pathogens, includ-
ing T. cruzi (29), with the bis-AIAs being the most effective of
the group (19).
A previous study reported the synthesis of dicationic m-ter-
phenyl derivatives and their biological effect against Trypanosoma
brucei rhodesiense, Plasmodium falciparum, Leishmania ama-
zonensis, and T. cruzi (16). Among these, bispyridylimidamides
were the most potent against the intracellular amastigote form of
the T. cruzi (Tulahuen strain, DTU VI). In the present study, we
further explored the phenotypic activity of 14 bis- and mono-
arylimidamides against BTs and intracellular forms of T. cruzi in
vitro and in vivo and extended the analysis to other parasite strains
(the Y and Colombiana strains, which belong to DTUs II and I,
respectively).
Structural variations of the test compounds used in this study
included those in AIA moieties as well as the central cores of the
molecules. Maximum potencies were observed with 35DAP073
and 35DAP081, each of which has two 2-pyridylimidamide
groups attached to an m-terphenyl nucleus and in which at
least one of the two AIA groups is meta to the central ring.
These two compounds were more potent than the correspond-
TABLE 4 Results of acute toxicity analysisa
Compound
Result after treatment at the following dose (mg/kg):
NOAEL
(mg/kg)0 12.5 25 50 100 200
35DAP073 NDE NDE NDE Loss of mouse
body wt
Tremors, ataxia Death 25
35DAP081 NDE Ataxia, tremors,
excitation and
vocalizationb
Ataxia, tremors,
excitation and
vocalizationb
Ataxia, tremors,
excitation and
vocalizationb
Ataxia, tremors,
excitation and
vocalizationb
Ataxia, tremors,
excitation and
vocalizationb

12. 5
a Escalating doses starting at 12.5 mg/kg and increasing to 200 mg/kg were administered i.p. in a 0.1-ml final volume to female Swiss Webster mice, using a single mouse per dose.
NOAEL, no-observed-adverse-effect level (for noninvasive parameters); NDE, no detectable effect.
b These effects were observed after 2 h of compound administration.
TABLE 5 Plasma biochemical analysis of female mice after 48 h of compound administration
Biochemical marker Compound
Result after treatment with the following dose (mg/kg)a:
0b 12.5 25 50 100 200
ALT 35DAP073 57	 8 58	 0 51	 0 88	 51 77	 41 ND
35DAP081 56	 0.7 67	 13 82	 8 102	 23 116	 11
CK 35DAP073 935	 226 635	 80 368	 0 701	 260 870	 646 ND
35DAP081 503	 145 509	 145 737	 0 1,681	 310 1,162	 452
AST 35DAP073 183	 16 109	 0 113	 0 152	 37 242	 105 ND
35DAP081 105	 16 143	 21 285	 55 422	 132 376	 229
BUN 35DAP073 46	 11 51	 16 34	 0 43	 2 55	 12 ND
35DAP081 37	 7 29	 7 31	 10 29	 0 60	 29
a Data are in milligrams per deciliter for blood urea nitrogen and units per liter for all other biochemical markers and are means	 SDs from two independent assays. Reference
values (CECAL/Fiocruz) are as follows: blood urea nitrogen (BUN), up to 29 mg/dl; alanine aminotransferase (ALT), up to 132 U/liter; aspartate transaminase (AST), up to 247
U/liter; creatine kinase (CK), up to 1,070 U/liter. P was
0.05 by ANOVA for all samples. ND, not determined due to animal death at the higher dose.
b Results are from one representative assay.
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ing bisphenylimidamides, 35DAP069 and 35DAP077. The dif-
ference in potencies between 35DAP073 and 35DAP069 was
greater than 60-fold but was less pronounced than that between
35DAP081 and 35DAP077. The bispyridylimidamides 35DAP073
and 35DAP081 were also more potent than the monopyri-
dylimidamides 35DAP092 and 38DAP096, thus demonstrating
the importance of two AIAmoieties. Compound 38DAP092, in
which the AIA group is meta to the central ring, was more
potent than its regioisomer, 38DAP096, which bears a para-
AIA moiety. None of the bis-AIAs with lone aromatic rings or
aliphatic chains between the two AIA functionalities (Fig. 2 and
3) showed detectable activity.
The most active molecule, the m-terphenyl bis-AIA 35DAP073,
showed an EC50 of 0.5Magainst trypomastigotes (Y strain) after
24 h and was more effective than the reference drug, Bz (13 M).
This amidine was also active against a highly naturally resistant
strain (Colombiana), exhibiting an EC50 of 3.8M. Analysis of its
activity against intracellular forms (Tulahuen strain) showed that
this bis-AIA (EC50  0.04 M) was about 50-fold more active
than Bz (2M). The greater effect against intracellular forms than
BT forms was dissociated from the ability of the amidines to
induce LB accumulation within mammalian host cells. The
biogenesis of lipid bodies is a central event in several processes
of cellular homeostasis, as well as during intracellular pathogen
infection (30, 31). LBs are recognized to be dynamic organelles
composed of a triglyceride and cholesteryl ester core with a
surrounding monolayer of phospholipid, cholesterol, and a va-
riety of associated proteins with diverse functions in cell me-
tabolism, signaling, and inflammation (14, 32). Under inflam-
matory and infectious conditions, prostaglandins and other
lipid mediators are mainly produced by LBs (33). Also, recent
findings showed that antimicrobial compounds may induce an
accumulation of lipid droplets in the cytoplasm of Candida spp.
(34) and protozoans (35). InMycobacterium leprae-infected cells,
LBs showed a strong ability to fuse, forming giant lipid droplets
(36). Since amidines can modulate the functional activities of
mammalian host cells linked to the control of parasite prolif-
eration and/or survival (37, 38) and LBs act on cellular metab-
olism, inflammation, and infectious conditions (14, 32), in the
present study we investigated whether the studied AIAs could
interfere with LB biogenesis and parasitism control in vitro.
Our data also demonstrated that 35DAP073 and 28SMB060
were able to induce LB biogenesis in cardiac cells at all times
tested (2 to 48 h), with cells treated with the two compounds
exhibiting similar morphological profiles. No correlation be-
tween the trypanocidal effect of amidines and LB accumulation
in CCs was found, but further studies are desirable to better
understand the consequences of the higher LB levels induced
by the amidines in the parasite as well the consequences on the
mammalian cell physiology, since this modulation may influ-
ence the growth of intracellular parasites (36).
Next, due to the excellent selective indexes of 35DAP073 and
FIG 5 Effect of 35DAP073 (20 to 5 mg/kg/day) and of benznidazole (100
mg/kg/day) administration at 5 and 8 dpi in amousemodel of experimentalT.
cruzi infection (Y strain). (A) Parasitemia levels; (B) percent cumulative mor-
tality.
FIG 6 Effect of daily administration of 35DAP073 (5 mg/kg/day), benznida-
zole (100 mg/kg/day), and 35DAP073 plus Bz (0.5 mg/kg/day and 100 mg/kg/
day, respectively) for 10 days in mouse models of experimental T. cruzi infec-
tion (Colombiana strain) when compounds were administered starting at 10
dpi. (A) Parasitemia levels; (B) percent cumulative mortality.
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35DAP081, both were tested for acute toxicity. The results show-
ed NOAEL values of 25 and 12.5 mg/kg for 35DAP073 and
35DAP081, respectively. Then, in vivo efficacy studies were con-
ducted with 35DAP073 at concentrations of
25mg/kg. Our data
demonstrated that 35DAP073 treatment of mice infected with the
Y and Colombiana strains resulted in a dose-dependent action of
35DAP073, leading to 96 to 46% reductions of parasitemia and
100% animal survival, with Bz showing a similar effect. Unfortu-
nately, as the 10 daily doses (at 5 mg/kg i.p.) were toxic for the
animals, combined therapy with 35DAP073 and Bz was tested
with the aim of reducing the toxic effects of the amidine. Mono-
therapy with 35DAP073 at only 0.5mg/kg/day was not attempted,
as previous data with related amidines demonstrated that doses of
5 mg/kg/day had only a mild effect on parasitemia control (23).
As was also found by our group (28) using the combination of Bz
with the amidine DB289, the association of 0.5 mg/kg 35DAP073
with Bz in the present study improved the control of parasite
proliferation, providing a 9-fold enhancement of activity com-
pared to that of Bz alone. qPCR analysis showed that the combi-
nation therapy was the best regimen, exhibiting parasitemia sup-
pression with no detectable toxicity to the animals. In this sense,
our results support further experimental investigations of this
compound class in association with licensed antiparasitic drugs
with the aim of contributing to the identification of novel alterna-
tives for the treatment of neglected parasitic diseases, such as Cha-
gas disease.
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